Actinium Pharmaceuticals (NYSE:ATNM) Receives Buy Rating from HC Wainwright

Actinium Pharmaceuticals (NYSE:ATNM)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $4.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 171.19% from the company’s current price.

Other equities analysts have also recently issued reports about the stock. B. Riley cut shares of Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $16.00 to $2.00 in a research note on Wednesday, August 7th. Maxim Group lowered their price target on shares of Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Finally, StockNews.com downgraded shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $11.40.

Actinium Pharmaceuticals Price Performance

Shares of ATNM stock traded down $0.18 on Friday, hitting $1.48. 379,311 shares of the stock were exchanged, compared to its average volume of 445,123. The stock has a market cap of $46.01 million, a price-to-earnings ratio of -0.98 and a beta of 0.14. Actinium Pharmaceuticals has a fifty-two week low of $1.33 and a fifty-two week high of $10.24. The business has a 50-day moving average of $1.80.

Hedge Funds Weigh In On Actinium Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. Interchange Capital Partners LLC bought a new position in Actinium Pharmaceuticals during the 3rd quarter worth $37,000. The Manufacturers Life Insurance Company bought a new position in Actinium Pharmaceuticals during the second quarter worth about $92,000. Creative Financial Designs Inc. ADV raised its stake in Actinium Pharmaceuticals by 183.0% in the 3rd quarter. Creative Financial Designs Inc. ADV now owns 63,785 shares of the company’s stock worth $120,000 after purchasing an additional 41,250 shares in the last quarter. Renaissance Technologies LLC bought a new stake in Actinium Pharmaceuticals in the 2nd quarter valued at about $142,000. Finally, Rhumbline Advisers grew its position in shares of Actinium Pharmaceuticals by 23.4% during the 2nd quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock worth $293,000 after purchasing an additional 7,525 shares in the last quarter. Institutional investors own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).